Multimarker RT-PCR for detection of minimal residual disease in breast cancer patients

with 2.4% in the MP group. The 2-year eventfree survival rate was significantly higher in patients who received thalidomide than in those who did not (54% vs 27%; P = 0.0006). A significant overall survival advantage for MPT was observed 9 months after randomization (P = 0.03). Thalidomide was, however, associated with a 22.7% increase in the rate of grade… CONTINUE READING